Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of zongertinib tablets from two manufacturers
NCT06360081Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zongertinib (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Zongertinib in Plasma Over the Time Interval From 0 to 72 hours and Maximum Measured Concentration of Zongertinib in Plasma at 72 hours. Started Apr 2024; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT06360081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360081.